developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
![Zentalis Pharmaceuticals logo](/files/LOGO/1725160-ZNTL.png)
Company profile
Ticker
ZNTL
Exchange
Website
CEO
Kimberly Lynn Blackwell
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Zeno Pharma, LLC, Zentalis Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Zeno Management, Inc. • Zeno Pharmaceuticals, Inc. • Zeno Alpha, Inc. • K-Group Alpha, Inc. • K-Group Beta, Inc. • Zentalis Pharmaceuticals Australia Pty Ltd. ...
ZNTL stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 24
8-K
Regulation FD Disclosure
3 Jun 24
DEFA14A
Additional proxy soliciting materials
29 May 24
8-K
Departure of Directors or Certain Officers
29 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
8-K
Departure of Directors or Certain Officers
11 Apr 24
Latest ownership filings
4
Jan Skvarka
21 Jun 24
4
Enoch Kariuki
21 Jun 24
4
David Michael Johnson
21 Jun 24
144
Notice of proposed sale of securities
31 May 24
4
Cam Gallagher
31 May 24
4
Luke Nathaniel Walker
29 May 24
3
Luke Nathaniel Walker
29 May 24
144
Notice of proposed sale of securities
9 May 24
4
DIANA HAUSMAN
9 May 24
3
Vincent Vultaggio
11 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.30 mm | 40.30 mm | 40.30 mm | 40.30 mm | 40.30 mm | 40.30 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.26 mm | 21.61 mm | 17.32 mm | 17.54 mm |
Cash used (since last report) | n/a | n/a | 31.92 mm | 83.55 mm | 66.98 mm | 67.83 mm |
Cash remaining | n/a | n/a | 8.38 mm | -43.26 mm | -26.69 mm | -27.53 mm |
Runway (months of cash) | n/a | n/a | 1.0 | -2.0 | -1.5 | -1.6 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 132 |
Opened positions | 60 |
Closed positions | 14 |
Increased positions | 31 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 1.17 tn |
Total shares | 81.36 mm |
Total puts | 2.30 k |
Total calls | 68.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Matrix Capital Management | 13.96 mm | $220.01 bn |
Eventide Asset Managment | 11.57 mm | $182.42 bn |
FMR | 10.64 mm | $167.75 bn |
BLK Blackrock | 4.65 mm | $73.22 bn |
Vanguard | 4.40 mm | $69.32 bn |
Citadel Advisors | 3.85 mm | $60.71 bn |
STT State Street | 3.79 mm | $59.66 bn |
T. Rowe Price | 3.49 mm | $55.00 mm |
T. Rowe Price Investment Management | 3.32 mm | $52.31 mm |
Capital International Investors | 2.82 mm | $44.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 24 | David Michael Johnson | Common Stock | Grant | Acquire A | No | No | 0 | 48,429 | 0.00 | 192,818 |
21 Jun 24 | Enoch Kariuki | Common Stock | Grant | Acquire A | No | No | 0 | 41,581 | 0.00 | 79,762 |
21 Jun 24 | Jan Skvarka | Common Stock | Grant | Acquire A | No | No | 0 | 41,581 | 0.00 | 89,551 |
31 May 24 | Cam Gallagher | Common Stock | Sell | Dispose S | No | Yes | 11.98 | 9,597 | 114.97 k | 633,680 |
24 May 24 | Luke Nathaniel Walker | Common Stock | Grant | Acquire A | No | No | 0 | 72,481 | 0.00 | 72,481 |
News
UBS Downgrades Zentalis Pharma to Neutral, Lowers Price Target to $5
20 Jun 24
12 Health Care Stocks Moving In Thursday's Intraday Session
20 Jun 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
19 Jun 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
19 Jun 24
Wells Fargo Downgrades Zentalis Pharma to Equal-Weight, Lowers Price Target to $9
18 Jun 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
26 Jul 24
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
25 Jul 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
24 Jul 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
12 Jul 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
10 Jul 24